Oxford Nanopore Technologies

56 articles about Oxford Nanopore Technologies

• The University of Queensland and Oxford Nanopore Technologies Team up to Accelerate Research Into Quality Control Testing for mRNA Vaccines

  9/21/2023

  Researchers at The University of Queensland are harnessing the latest sequencing technology developed by UK-based biotech Oxford Nanopore Technologies to analyse mRNA vaccines and therapies.

• NIH Center for Alzheimer’s and Related Dementias publication shows comprehensive, high accuracy sequencing approach, using new Oxford Nanopore sequencing chemistry

  9/19/2023

  Oxford Nanopore sequencing technology has been used by a team led by researchers at the National Institutes of Health Center for Alzheimer's and Related Dementias (CARD), the University of California, Santa Cruz and the National Cancer Institute, to develop a protocol for highly accurate whole human genome sequencing, at scale, that provides a comprehensive view of haplotype-resolved variation and methylation.

• Oxford Nanopore Technologies and Geneyx Announce the First Scalable Software Solution to Advance the Future Clinical Use of Nanopore Sequencing

  6/9/2023

  Oxford Nanopore Technologies plc and Geneyx, an AI platform for human genetic analysis and interpretation, are aiming to team up to develop the first scalable software solution for the end-to-end analysis and clinical reporting of nanopore sequencing data.

• Oxford Nanopore and bioMérieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics

  4/14/2023

  Oxford Nanopore Technologies plc (LSE: ONT) (“Oxford Nanopore”) and bioMérieux SA today announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.

• Oxford Nanopore and PathoQuest announce the first steps in a strategic collaboration to bring the first GMP-accredited, nanopore-based biologics genetic characterisation test to market

  3/21/2023

  Oxford Nanopore Technologies plc and PathoQuest announce the agreement of a MOU for a collaboration to commercialise a transformational Integration Site Analysis test to better meet the evolving needs of the biopharmaceutical industry and the advancement of biological therapeutics.

• Oxford Nanopore and 4bases Announce Collaboration to Combine Nanopore Sequencing Devices and 4bases Kits to Support Rapid, High-accuracy Analyses in Human and Cancer Genetics, with a First Target of Same-day BRCA1 and BRCA2 Analysis

  3/20/2023

  Oxford Nanopore Technologies plc and 4bases, a Switzerland-based company, specialising in kits for sequencing and bioinformatic tools, announce a collaboration to make available 4bases kits with Oxford Nanopore sequencing technology.

• Oxford Nanopore Technologies and Cyclomics begin developer testing on non-invasive method for accurate and fast detection of molecules associated with cancer

  3/16/2023

  Oxford Nanopore Technologies and Dutch start-up Cyclomics announced the ‘developer access’ of a new research workflow: the world’s first nanopore sequencing-based solution for ultra-sensitive detection of circulating tumour DNA.

• Oxford Nanopore Technologies Teams up With UPS Healthcare to Accelerate Delivery of New-Generation DNA Sequencing Technology to More Customers in Locations Across Asia Pacific

  2/16/2023

  Oxford Nanopore Technologies announced an extension of its collaboration with UPS Healthcare to accelerate the delivery of Oxford Nanopore DNA/RNA sequencing products and consumables across the Asia Pacific region.

• Bio-Techne and Oxford Nanopore Technologies partner to bring innovative reproductive health and carrier screening solutions to the market

  12/1/2022

  Asuragen, a Bio-Techne brand and Oxford Nanopore Technologies plc, announce a collaboration to develop assays designed to deliver more accurate and reliable options for reproductive health and carrier screening.

• Oxford Nanopore Technologies Announces New Collaboration With 10x Genomics to Make Single-cell and Spatial Full-length Isoform Transcript Sequencing Accessible to Any Laboratory

  10/27/2022

  Oxford Nanopore Technologies plc (Oxford Nanopore) today announces a collaboration with 10x Genomics, to enable a streamlined workflow for sequencing full-length transcripts in single reads on highly accessible Oxford Nanopore devices.

• 

  The Top 5 Genome Sequencing Companies by Revenue

  9/30/2022

  The gene sequencing industry has really taken off in recent years. Here's a look at the top five genome sequencing companies, ranked by revenue.

• ONT releases Remora: Most Comprehensive Methylation

  5/26/2022

  Oxford Nanopore users have easy access to precise whole genome methylation detection from PCR-free nanopore sequencing using Remora.

• Oxford Nanopore Announces Tech Updates

  5/20/2022

  At the annual London Calling conference, CTO Clive Brown and colleagues James Clarke, Stuart Reid, Lakmal Jayasinghe and Rosemary Sinclair Dokos have provided an Oxford Nanopore tech update summarising the status of its nanopore sensing platform, key recent developments that drive improved accuracy and increased output, and outlined the vision for future developments.

• ONT Opens User Conference, Rich Science Programme

  5/19/2022

  The annual London Calling genomics conference, hosted by Oxford Nanopore, starts , featuring more than 80 scientific talks across a range of disciplines, with thousands of scientists expected to attend either in person or online.

• ONT Chosen for Comprehensive Human Genome Program

  5/13/2022

  Oxford Nanopore sequencing technology is to be used by a group of researchers led by Evan Eichler, University of Washington and Danny Miller, University of Washington and Seattle Children's Hospital, to initially sequence 500 of the 1000 Genomes Project samples.

• Genomics England Expands Nanopore Use in Cancer

  4/4/2022

  Oxford Nanopore has announced the next steps in its collaboration with Genomics England, which is using nanopore technology in an ongoing proof-of-concept project to evaluate the clinical and research applications of comprehensive genomic analysis of cancer tumours.

• ONT Shows New High-Accuracy, High-Output Chemistry

  3/30/2022

  Nanopore sequencing enables the analysis of native DNA/RNA and sequencing of any length fragment from short to ultra-long, enabling the elucidation of all types of genetic and epigenetic variants.

• Oxford Nanopore Technologies PLC Announces Nanopore Sequencing Profiles TB: Find Evaluation

  3/24/2022

  Oxford Nanopore announces positive evaluation of new method for rapid drug-resistant tuberculosis profiling

• Oxford Nanopore Releases Short Fragment Mode

  3/23/2022

  Short Fragment Mode will be integrated into the operating software that drives nanopore devices, allowing sequencing of fragments as short as 20 bases on nanopore platforms.

• Oxford Nanopore Technologies plc Announces Publication: Nanopore IDs >50 Genetic Diseases

  3/8/2022

  A new DNA sequencing based test method developed by a team led by Ira Deveson, Head of Genomics Technologies at the Garvan Institute of Medical Research and collaborators, has been shown to screen for more than 50 genetic neurological and neuromuscular diseases.